News & Events
A new Monash biotech company called Phrenix Therapeutics has received funding to advance research to develop new therapeutics for cognitive disorders, particularly in schizophrenia.
In the fight for better mental health services, support and outcomes for millions of people around the world, the data can no longer be ignored: psychedelics might just be the key to unlocking a revolution in mental health.
In this episode of What Happens Next?, Dr Susan Carland talks to Dr Paul Liknaitzky and Dr Meaghan O’Donnell.
On a new episode of What Happens Next?, Susan Carland considers the political landscape surrounding drug legalisation, the cultural context of drug use and the promise of psychedelic therapy.
Monash University today will launch an end-to-end, cross-disciplinary Centre to drive novel psychiatric drug discovery, as well as new approaches to neuromedicine-assisted psychotherapies, for the treatment of mental health disorders.